Unknown

Dataset Information

Comparative Resistance to Teriparatide-Induced Bone Resorption With Denosumab or Alendronate.


ABSTRACT:

Context

In postmenopausal osteoporotic women, denosumab fully inhibits teriparatide-induced bone resorption at approved doses. This property of denosumab is distinct from that of alendronate and likely contributes to the efficacy of combination denosumab and teriparatide therapy. Whether denosumab fully inhibits bone resorption when challenged by a higher dose of teriparatide is unknown.

Objective

We aimed to define the comparative ability of denosumab and alendronate to block the acute proresorptive effects of high-dose teriparatide.

Design, setting, and participants

In this randomized controlled trial, bone resorption (serum C-telopeptide [CTX]) was measured in 25 postmenopausal women prior to and 4 hours after a single 40-μg sc teriparatide injection. Subjects then

SUBMITTER: Tsai JN 

PROVIDER: S-EPMC5393530 | biostudies-literature | 2015 Jul

REPOSITORIES: biostudies-literature